Therapeutics

Ascenta Capital Fund I is the inaugural venture fund launched by Ascenta Capital, with a strong focus on biotechnology and therapeutic innovation. It is designed to back companies at early human development stages that are building multi‑medicine platforms, blending scientific rigor with translational ambition. The fund aims to partner closely with management teams, offering not only capital but also domain expertise in clinical, regulatory, and operational strategy. Since its founding in 2023, Ascenta has rapidly built momentum, closing Fund I at approximately USD 325 million. It is selectively investing and concentrating on a small number of promising biotech companies rather than a broad portfolio, positioning itself as a deeply engaged and strategic investor. The fund targets companies that are moving from preclinical to early-stage clinical development (Phase 1 / Phase 2), especially those with multi‑therapeutic pipelines or platform technologies that can generate modular or complementary product portfolios. Ascenta brings to its portfolio teams both capital and high‑touch support in scientific, regulatory, and business strategy to accelerate translation into human clinical data. Geographically, Ascenta Capital Fund I primarily invests in U.S.-based biotech and life sciences companies, often in therapeutics, drug development, or platform biotech domains. It tends to lead or co‑lead deals in development-stage biotech rounds, typically in the mid-to-later VC stages, deploying meaningful capital per deal to ensure alignment and impact.

Deerfield Healthcare Innovations Fund III is the third installment in Deerfield Management's series of venture capital funds dedicated to advancing healthcare. Launched in May 2025, the fund has secured over $600 million in commitments, aiming to invest in promising therapeutics, improvements to healthcare delivery, and paradigm-shifting technologies, including machine learning and artificial intelligence. The fund's strategy leverages Deerfield's collaborations with 29 leading research institutions and nine industry partners. Through its in-house ecosystem, including specialized teams like Deerfield Discovery and Development (3DC) and Deerfield Intelligence, the firm identifies and advances innovative products, services, and technologies. These efforts are often in partnership with Deerfield-founded entities such as Deerfield Catalyst and Genscience. Operating from its twelve-story healthcare innovation campus, Cure, in New York City, Deerfield provides state-of-the-art research laboratories and convening spaces to support health innovators. Consistent with its long-standing practice, a portion of the profits from Healthcare Innovations Fund III not allocated to the fund's limited partners will be donated to the Deerfield Foundation, a not-for-profit organization focused on improving the health of children worldwide.

Mérieux Innovation 2 (MI2) is the second-generation venture capital fund managed by Mérieux Equity Partners, focused on advancing innovation in the healthcare sector. Building on the success of its predecessor, MI2 is designed to support early-stage companies with high-impact solutions across diagnostics, medical devices, and pharmaceutical services. The fund targets platform-based business models with validated proof of concept, offering scalability and long-term growth potential. MI2 combines capital investment with strategic guidance and access to a robust healthcare ecosystem, helping portfolio companies accelerate development and go-to-market strategies. MI2 has received the prestigious Tibi label, highlighting its commitment to driving technological innovation within France and the broader European healthcare landscape. It aims to generate strong returns while contributing meaningfully to patient care and clinical outcomes. The fund’s first investment is a €6 million commitment to DeepUll, a Spanish diagnostics company developing rapid sepsis detection technology. This aligns with MI2’s goal of supporting transformative platforms that address critical medical needs.

Sofinnova Capital XI is the eleventh iteration of Sofinnova Partners’ flagship venture capital strategy, closing with €650 million in commitments. This oversubscribed fund reflects strong demand from a diversified global investor base, including sovereign wealth funds, corporates, insurers, foundations, and family offices. A majority of existing limited partners returned, alongside new institutional investors, underscoring confidence in the firm’s long-standing life sciences expertise.Focused on early-stage investing, Sofinnova Capital XI targets seed and Series A rounds in the biotechnology and medical device sectors. The fund is designed to take meaningful initial stakes and support portfolio companies through multiple financing rounds. This capital will fuel high-potential ventures working to transform scientific discoveries into patient-ready solutions, particularly in areas with significant unmet medical needs.The fund will invest across Europe and North America, leveraging Sofinnova’s presence in Paris, London, and Milan, as well as its networks in the United States. The cross-border investment team will source and nurture opportunities at the intersection of innovation and clinical translation. The firm’s hands-on approach includes company building, board-level involvement, and strategic guidance from preclinical development to commercialization.